Verastem, Inc. (VSTM)
6.85
-0.04
(-0.58%)
USD |
NASDAQ |
Aug 24, 16:00
6.85
0.00 (0.00%)
After-Hours: 20:00
Verastem EPS Diluted (Quarterly) : -0.3463 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3463 |
| March 31, 2026 | -0.3723 |
| December 31, 2025 | -0.3947 |
| September 30, 2025 | -1.347 |
| June 30, 2025 | -0.6247 |
| March 31, 2025 | -0.9618 |
| December 31, 2024 | -1.325 |
| September 30, 2024 | -0.5953 |
| June 30, 2024 | -0.3074 |
| March 31, 2024 | -1.262 |
| December 31, 2023 | -1.021 |
| September 30, 2023 | -0.7467 |
| June 30, 2023 | -1.369 |
| March 31, 2023 | -0.9396 |
| December 31, 2022 | -0.9863 |
| September 30, 2022 | -1.101 |
| June 30, 2022 | -1.413 |
| March 31, 2022 | -1.093 |
| December 31, 2021 | -1.083 |
| September 30, 2021 | -1.520 |
| June 30, 2021 | -1.179 |
| March 31, 2021 | -1.051 |
| December 31, 2020 | -1.403 |
| September 30, 2020 | 0.9287 |
| June 30, 2020 | -1.669 |
| Date | Value |
|---|---|
| March 31, 2020 | -4.215 |
| December 31, 2019 | -6.096 |
| September 30, 2019 | -4.872 |
| June 30, 2019 | -6.854 |
| March 31, 2019 | -6.191 |
| December 31, 2018 | -4.459 |
| September 30, 2018 | -3.531 |
| June 30, 2018 | -3.60 |
| March 31, 2018 | -4.92 |
| December 31, 2017 | -5.16 |
| September 30, 2017 | -7.32 |
| June 30, 2017 | -4.32 |
| March 31, 2017 | -4.20 |
| December 31, 2016 | -3.84 |
| September 30, 2016 | -2.52 |
| June 30, 2016 | -2.76 |
| March 31, 2016 | -2.64 |
| December 31, 2015 | -3.84 |
| September 30, 2015 | -5.04 |
| June 30, 2015 | -5.04 |
| March 31, 2015 | -5.52 |
| December 31, 2014 | -6.36 |
| September 30, 2014 | -6.24 |
| June 30, 2014 | -6.12 |
| March 31, 2014 | -6.12 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Ironwood Pharmaceuticals, Inc. | 0.3068 |
| Dianthus Therapeutics, Inc. | -0.8962 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -34.67M |
| Revenue (Quarterly) | 40.08M |
| Total Expenses (Quarterly) | 74.75M |
| Enterprise Value | 571.40M |
| Gross Profit Margin (Quarterly) | 89.92% |
| Profit Margin (Quarterly) | -86.51% |
| Earnings Yield | -35.91% |
| Normalized Earnings Yield | -29.27 |